These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of orthostatic hypotension in Parkinson's disease. Oka H; Yoshioka M; Onouchi K; Morita M; Mochio S; Suzuki M; Hirai T; Ito Y; Inoue K Brain; 2007 Sep; 130(Pt 9):2425-32. PubMed ID: 17673498 [TBL] [Abstract][Full Text] [Related]
6. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Churchyard A; Mathias CJ; Lees AJ Mov Disord; 1999 Mar; 14(2):246-51. PubMed ID: 10091617 [TBL] [Abstract][Full Text] [Related]
7. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Bhattacharya KF; Nouri S; Olanow CW; Yahr MD; Kaufmann H Parkinsonism Relat Disord; 2003 Mar; 9(4):221-4. PubMed ID: 12618057 [TBL] [Abstract][Full Text] [Related]
8. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034 [TBL] [Abstract][Full Text] [Related]
9. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Lees AJ BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803 [TBL] [Abstract][Full Text] [Related]
16. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Fernandez HH; Chen JJ Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750 [TBL] [Abstract][Full Text] [Related]
17. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926 [TBL] [Abstract][Full Text] [Related]
18. Twenty-four-hour ambulatory blood pressure and heart rate profiles in diagnosing orthostatic hypotension in Parkinson's disease and multiple system atrophy. Vichayanrat E; Low DA; Iodice V; Stuebner E; Hagen EM; Mathias CJ Eur J Neurol; 2017 Jan; 24(1):90-97. PubMed ID: 27718292 [TBL] [Abstract][Full Text] [Related]